Masahiro Michishita
President chez Pacific Rim Ventures Co. Ltd.
Profil
Dr. Masahiro Michishita, MD PhD, is President at Pacific Rim Ventures Co. Ltd.
He is on the Board of Directors at UMN Pharma, Inc.
Prior to establishing PRV, Dr. Michishita was Investment Officer, International Investment Group, JAFCO Co., Ltd.
In that capacity he invested in medical device, biopharmaceutical, and healthcare information technology companies in the US, Europe and Israel.
Previously Dr. Michishita was employed by Procter & Gamble Far East, Inc., the Boston Consulting Group, and Eisai Co., Ltd., Japan.
He was also a research fellow in the Leukocyte Biology & Inflammation Program at Massachusetts General Hospital and Harvard Medical School.
Dr. Michishita is board-certified in Internal Medicine and worked at the Hematology-Oncology Division of Kyoto University Hospital.
His research has been published in Cell, J.
Biological Chemistry, Exp.
Cell Res.
and J.
Immunology.
Dr. Michishita has been Visiting Professor of Akita University and Special Advisor in biotechnology for ASTEC (Advanced Science and Technology Enterprise Corporation) which is a venture incubation company to support commercialization of early stage technologies from the University of Tokyo
He received his doctorate degree from Kanazawa University and a doctorate degree from Kyoto University.
Postes actifs de Masahiro Michishita
| Sociétés | Poste | Début |
|---|---|---|
Pacific Rim Ventures Co. Ltd.
 Pacific Rim Ventures Co. Ltd. Investment ManagersFinance Pacific Rim Ventures Co. Ltd. (PRV) is an independent boutique-sized investment management firm established in 1999. PRV is headquartered in Tokyo with an office in Akita as well as U.S. offices in Colorado and North Carolina. The firm specializes in venture capital investing. They manage the Pacific Rim AQUA Life Science series of investment funds. PRV's culture is grounded in the extensive scientific, medical and pharmaceutical background of the partners. PRV has formed strategic alliances with Recruit Co., a leader in managing and commercializing academic intellectual property throughout Japan, and with ASTEC-Advanced Science and Technology Enterprise Corporation, a commercialization interface handling IP issues for the University of Tokyo. | President | 01/04/1999 |
Anciens postes connus de Masahiro Michishita
| Sociétés | Poste | Fin |
|---|---|---|
| UMN PHARMA INC. | Fondateur | - |
Formation de Masahiro Michishita
| Kyoto University | Doctorate Degree |
| Kanazawa University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Pacific Rim Ventures Co. Ltd.
Pacific Rim Ventures Co. Ltd. Investment ManagersFinance Pacific Rim Ventures Co. Ltd. (PRV) is an independent boutique-sized investment management firm established in 1999. PRV is headquartered in Tokyo with an office in Akita as well as U.S. offices in Colorado and North Carolina. The firm specializes in venture capital investing. They manage the Pacific Rim AQUA Life Science series of investment funds. PRV's culture is grounded in the extensive scientific, medical and pharmaceutical background of the partners. PRV has formed strategic alliances with Recruit Co., a leader in managing and commercializing academic intellectual property throughout Japan, and with ASTEC-Advanced Science and Technology Enterprise Corporation, a commercialization interface handling IP issues for the University of Tokyo. | Finance |
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
